These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29303717)

  • 21. The needs of refugee women: a human-rights perspective.
    Beyani C
    Gend Dev; 1995 Jun; 3(2):29-35. PubMed ID: 12290124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yemen's cholera epidemic may have peaked, says WHO.
    Dyer O
    BMJ; 2017 Jun; 357():j3131. PubMed ID: 28659262
    [No Abstract]   [Full Text] [Related]  

  • 23. Ethnic cleansing in Myanmar: the Rohingya crisis and human rights.
    Beyrer C; Kamarulzaman A
    Lancet; 2017 Sep; 390(10102):1570-1573. PubMed ID: 28943266
    [No Abstract]   [Full Text] [Related]  

  • 24. Our responsibility to protect the Rohingya.
    The Lancet
    Lancet; 2017 Dec; 390(10114):2740. PubMed ID: 29303713
    [No Abstract]   [Full Text] [Related]  

  • 25. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crisis-driven cholera resurgence switches focus to oral vaccine.
    Bull World Health Organ; 2018 Jul; 96(7):446-447. PubMed ID: 29962546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health and human rights in eastern Myanmar after the political transition: a population-based assessment using multistaged household cluster sampling.
    Parmar PK; Barina CC; Low S; Tun KT; Otterness C; Mhote PP; Htoo SN; Kyaw SW; Lwin NA; Maung C; Moo NM; Oo EK; Reh D; Mon NC; Singh N; Goyal R; Richards AK
    PLoS One; 2015; 10(5):e0121212. PubMed ID: 25970445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh.
    Chowdhury F; Bhuiyan TR; Akter A; Bhuiyan MS; Khan AI; Hossain M; Tauheed I; Ahmed T; Islam S; Rafique TA; Siddique SA; Harun NB; Islam K; Clemens JD; Qadri F
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0007989. PubMed ID: 32176695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress towards interruption of wild poliovirus transmission in 2005.
    Wkly Epidemiol Rec; 2006 Apr; 81(17):165-72. PubMed ID: 16673506
    [No Abstract]   [Full Text] [Related]  

  • 31. Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia.
    An F; Wang H; Liu Z; Wu F; Zhang J; Tao Q; Li Y; Shen Y; Ruan Y; Zhang Q; Pan Y; Zhu W; Qin H; Wang Y; Fu Y; Feng Z; Zhai Z
    Nat Commun; 2020 Nov; 11(1):5928. PubMed ID: 33230103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.
    Gill S; Porter DL
    Expert Opin Biol Ther; 2014 Jan; 14(1):37-49. PubMed ID: 24261468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospect for immunotherapy of acute lymphoblastic leukemia.
    Velders MP; ter Horst SA; Kast WM
    Leukemia; 2001 May; 15(5):701-6. PubMed ID: 11368429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
    Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR
    Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. International security: what nuclear weapon states have not learnt in 75 years.
    Birch M; van Bergen L
    Med Confl Surviv; 2020 Sep; 36(3):203-205. PubMed ID: 32895013
    [No Abstract]   [Full Text] [Related]  

  • 36. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
    Yang X; Dai H; Kang L; Qu C; Li Z; Yin J; Qiu H; Fu C; Han Y; Jin Z; Ma X; Zhu X; Yu L; Wu D; Tang X
    Hematol Oncol; 2019 Dec; 37(5):655-658. PubMed ID: 31656047
    [No Abstract]   [Full Text] [Related]  

  • 37. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.
    Zhang X; Li JJ; Lu PH
    Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy.
    Rosenbaum L
    N Engl J Med; 2017 Oct; 377(14):1313-1315. PubMed ID: 28902570
    [No Abstract]   [Full Text] [Related]  

  • 40. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
    Wang M
    Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.